WHILE it's long been known that patients in end-of-life care are frequently overprescribed medicines of limited or no value at that stage, new research by US and UK scientists has confirmed the frequency of such practices.
The British Journal of Clinical Pharmacology published study found patients who later died of lung cancer, were still taking preventative medicines such as those for diabetes, hypertension, high cholesterol and blood clots.
Authors said there was scope for deprescribing for these patients who were in end-of-life care.
CLICK HERE to access the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Sep 18
